Navigation Links
Protein therapy may reduce infarct size in heart attack patients

Researchers are searching for new methods and therapies to reduce infarct size and improve blood flow to the heart muscle in patients who experience myocardial infarction (MI), or heart attack.

In a study presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit in New Orleans, La., a team from the Duke Clinical Research Institute presented the results from a Phase 1 study evaluating a novel protein kinase C inhibitor that had shown benefit in animal models, but had not previously been studied in humans. This first-in-human study suggests that this new drug may have promise as a potential therapeutic agent in heart attack patients. Innovation in Intervention: i2 Summit is an annual meeting for practicing cardiovascular interventionalists sponsored by the American College of Cardiology in partnership with the Society for Cardiovascular Angiography and Interventions.

Heart attacks are caused by blockages in the coronary artery preventing blood flow to the heart muscle. Restoring blood flow to the heart improves clinical outcomes in heart attack patients, but there remains significant injury to heart muscle cells. Protein kinase C (PKC) is activated in these heart cells, initiating a series of events that can cause further damage to the heart. Animal studies have suggested that KAI-9803, an inhibitor of PKC, may reduce injury in damaged heart muscle cells, but this class of therapies had not previously been studied in heart attack patients.

In the DELTA MI trial, the DCRI team evaluated KAI-9803 in 154 patients with anterior ST-elevation MI undergoing primary percutaneous coronary intervention with balloon angioplasty and coronary stent implantation. Patients were randomized 2:1 to receive intracoronary injections of the active study drug (KAI-9803) vs. placebo in four dose groups (0.05, 0.5, 1.25 or 5.0 mg of KAI-9803). Researchers performed tests to assess heart function at various time points and a ssessed safety and cardiac outcomes through six months. This trial was designed as an exploratory study to assess the potential impact of KAI-9803 in this “first-in-human?study.

Results indicate that KAI-9803 may be associated with less myocardial necrosis with lower CK-MB AUC values at all dose levels. Furthermore, improved tissue perfusion (measured during coronary angiography after stent implantation and by continuous electrocardiogram recordings) and reduced infarct size (measured 14 days after the heart attack) were observed at the 0.5 mg (infarct size 23 vs. 29.5% of the left ventricle) and 1.25 mg (infarct size 32.5 vs. 43% of the left ventricle) dose levels. No major safety concerns were demonstrated with the therapy since the incidence of serious adverse events was similar among patients treated with KAI-9803 compared to placebo, even at the highest dose levels of the study.

"In this early study, we believe the data suggest a potential therapeutic role for KAI-9803,?said Matthew Roe, M.D., of the Duke Clinical Research Institute and lead author of the study. “The drug was associated with a favorable safety and tolerability profile and based on this ‘first in human?trial, we are interested in pursing larger studies to determine the therapeutic value of this treatment for heart attack patients receiving reperfusion therapy."


'"/>

Source:American College of Cardiology


Related biology news :

1. Quantum Dots Research Leads to New Knowledge about Protein Binding in Plants
2. Protein discovery could unlock the secret to better TB treatment
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. An HIV Protein Plays a Surprising Role in Gene Activation
5. Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease
6. New SARS Protein Linked To Important Cell Doorway
7. The Shapes Of Life: NIGMS Project Yields More Than 1,000 Protein Structures
8. PANTHER Protein Classification System Database 5.0
9. Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimers, Parkinsons Disease
10. Newly Discovered Compound Blocks Known Cancer-Causing Protein
11. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2016)... PUNE, India , January 21, 2016 /PRNewswire/ ... According to a new market research report "Emotion ... Learning, and Others), Software Tools (Facial Expression, Voice ... and Regions - Global forecast to 2020", published ... Market is expected to reach USD 22.65 Billion ...
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
(Date:1/13/2016)... 13, 2016 --> ... new market report titled - Biometric Sensors Market - Global ... - 2023. According to the report, the global biometric sensors market was ... to reach US$1,625.8 mn by 2023, expanding at a ... of volume, the biometric sensors market is expected to ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... ... February 11, 2016 , ... ... new stem cell treatment clinic in Quito, Ecuador. The new facility will provide ... applications to patients from around the world. , The new GSCG clinic ...
(Date:2/10/2016)... Ky. , Feb. 10, 2016 NX ... utilizing its proprietary NeXosome® technology for early warning ... of its most recent study by Dr. ... at the Society for Maternal Fetal Medicine,s (SMFM) annual ... GA, February 1-6 th , 2016.  The presentation reported ...
(Date:2/10/2016)... plc (NYSE: AGN ) a leading global pharmaceutical ... CEO and President, will be featured as the keynote ... Capital Markets Healthcare Conference on Tuesday, February 23, 2016 ... Hotel in New York, NY . ... accessed on Allergan,s Investor Relations web site at ...
(Date:2/10/2016)... ... ... LATHAM, NEW YORK... Marktech Optoelectronics will feature their new high-speed InGaAs ... Moscone Center from February 16-18, 2016, and at the healthcare-focused BiOS Expo on February ... standard packages feature a TO-46 metal can with active areas of 1.0mm and 1.5mm ...
Breaking Biology Technology: